American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Berger
    Berger
  7. Norton
    Norton
  8. Schultz
    Schultz
  9. Weigelt
    Weigelt
  10. Chandarlapaty
    Chandarlapaty

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II trial of intraperitoneal (IP) cisplatin (CDDP) with IP gemcitabine (GEM) in patients (pts) with epithelial ovarian cancer
    Meeting Abstract

    Sabbatini, P.; Aghajanian, C.; Hensley, M.; Tong, W.; Soignet, S.; Hoskins, W.; O'Flaherty, C.; Pezzulli, S.; Barakat, R.; Spriggs, D.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • A phase I study of a novel antimicrotubule agent: T138067
    Meeting Abstract

    Budman, D. R.; Berg, W. B.; Spriggs, D. R.; Vongprachnach, P.; O'Mara, V.; Wright, M.; Walling, J.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Phase I and pharmacology study of the epothilone B analog BMS-247550 in patients with advanced cancer
    Meeting Abstract

    Spriggs, D.; Soignet, S.; Bienvenu, B.; Letrent, S.; Lebwohl, D.; Burris, H.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Clinical development of PS-341: From mice to man
    Meeting Abstract

    Elliott, P. J.; Aghajanian, C.; Cusack, J.; Orlowski, R.; Logothetis, C.; Papandreou, C.; Pien, C.; Smith, M.; Spriggs, D.; Adams, J.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Ecteinascidin 743, a novel chemotherapeutic agent that targets transcriptional activation of a subset of genes, including MDR1
    Meeting Abstract

    Scotto, K. W.; Jin, S. K.; Gorfajn, B.; Hu, Z.; Shtil, A.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Ecteinascidin 743 (ET-743) and doxorubicin produce synergistic cytotoxic effects in soft tissue sarcoma lines HT-1080 and HS-18
    Meeting Abstract

    Takahashi, N.; Li, W. W.; Faircloth, G.; Jimeno, J.; Bertino, J. R.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • In vitro safety toxicology of kahalalide F, a marine natural product with chemotherapeutic potential against selected solid tumors
    Meeting Abstract

    Luber-Narod, J.; Smith, B.; Grant, W.; Jimeno, J. M.; Lopez-Lazaro, L.; Scotto, K.; Shtil, A.; Faircloth, G. T.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • A novel cell cycle inhibitor (Ro 31-7453): A clinical and pharmacokinetic study in patients with solid tumors
    Meeting Abstract

    Soignet, S.; Bienvenu, B.; Pezzulli, S.; Ng, K.; Vongphrachanh, P.; Breimer, L.; Zhi, J. G.; Dhingra, K.; Huber, M. H.; Spriggs, D.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Pharmacokinetics of arsenic trioxide (ATO) in patients with relapsed/refractory acute promyelocytic leukemia (APL)
    Meeting Abstract

    Soignet, S.; Bienvenu, B.; Warrell, R. P.; Ellisson, R.; Spriggs, D.; Brannan, M.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • Induced gene expression in SK-OV-3 cells treated with cisplatin or ZD0473, a novel non-cross resistant platinum complex
    Meeting Abstract

    Yan, J.; Dizon, D.; Spriggs, D.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: